scorecardresearch
Add as a preferred source on Google
Wednesday, November 5, 2025
TopicCovaxin

Topic: Covaxin

This is how Bharat Biotech changed expert panel’s mind on Covaxin in a day and got approval

Minutes of the meetings held by the expert panel tell us what convinced it to change its mind about Covaxin despite incomplete phase 3 trial data.

After public spat, Bharat Biotech & SII jointly pledge smooth roll out of Covid vaccines

The joint statement comes after Bharat Biotech MD Dr Krishna Ella hit out at Serum CEO Adar Poonawalla’s comment that only Pfizer, Moderna, Oxford vaccines were effective.

Serum Institute, Bharat Biotech, Cadila vaccines — sifting science from non-science

In episode 653 of ‘Cut The Clutter’, the first in the new year, ThePrint’s Editor-in-Chief Shekhar Gupta explained working of Covaxin, Covishield & Zydus Cadila’s DNA vaccine.

DCGI’s Covaxin ‘approval’ is political jumla. It reinforces idea of Modi’s Atmanirbhar Bharat

The Modi govt must not damage India’s competitive advantage in vaccines & pharmaceuticals through absurd benchmarks that will not be trusted by other countries.

Oxford trial ‘lousy’, we’ll be ready with 70 cr Covaxin doses this year, says Bharat Biotech

Bharat Biotech MD Dr Krishna Ella says they gave ‘excellent safety data tested on around 25,000 participants’ & their efficacy data will be available by February-March.

Tackling India’s vaccine hesitancy, and Modi’s ‘world topper’ trophy

The best cartoons of the day, chosen by the editors at ThePrint.

After Congress’ Jairam & Tharoor, now Milind Deora questions ‘speedy’ approval for Covaxin

Milind Deora joins Shashi Tharoor and Jairam Ramesh in questioning ‘premature approval’ for Bharat Biotech’s Covaxin even though the Congress has officially welcomed the vaccine.

Oxford vaccine to cost Rs 219-292 to govt, double for private buyers, says Adar Poonawalla

The Serum Institute of India CEO said Covishield will be sold to the govt and Global Alliance for Vaccines and Immunization countries first and on the private market later.

Why Bharat Biotech’s Covaxin is the object of national pride & scientific scepticism

India, which makes more than 60% of the world’s vaccines, risking transparency with its hasty vaccine approval will directly affect drug pricing and global acceptance.

Thank you, Akhilesh Yadav. BJP can take its vaccine nationalism from here

Samajwadi Party chief Akhilesh Yadav erred big time with his ‘BJP’s vaccine’ comment. But it highlights how BJP is winning the battle of public perception in Covid management.

On Camera

Nitish Kumar’s journey from endurance to exhaustion

Nitish Kumar has mastered the rhythm of renewal in Bihar. In a democracy of churn and chance, endurance may be the rarest—and most refined—form of political art.

India may cancel green projects struggling to find clients

While the move could free up grid capacity struggling to keep up with rapid renewable rollout, it would be a major setback for green ambitions. India aims to double clean power capacity to 500 gigawatts by the end of the decade.

‘Let them see’: Putin says new nuclear-powered missiles in the making, in message to Washington

At a ceremony felicitating Russian military engineers, Putin highlights Moscow’s 'parity' in defence technologies for the next century.

Trump’s trade wars have rewritten powerplay, but India didn’t get the memo

This world is being restructured and redrawn by one man, and what’s his power? It’s not his formidable military. It’s trade. With China, it turned on him.